Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations - Sorbonne Université Access content directly
Journal Articles Journal of clinical lipidology Year : 2019

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations

Dates and versions

hal-03970307 , version 1 (02-02-2023)

Identifiers

Cite

Paul Hopkins, Michel Krempf, Eric Bruckert, Stephen Donahue, Feng Yang, et al.. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. Journal of clinical lipidology, 2019, 13 (6), pp.970-978. ⟨10.1016/j.jacl.2019.10.007⟩. ⟨hal-03970307⟩
6 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More